Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSDI Group Regulatory News (SDI)

Share Price Information for SDI Group (SDI)

Share Price is delayed by 15 minutes
Get Live Data
88.00    0.00 (0.00%)
Bid:
87.00
Ask:
89.00
Spread: 2.00 (2.299%)
Market Cap: £92.02m
SDI Live PriceLast checked at - London Stock Exchange

Intraday SDI Group Share Chart

Half Yearly Report

25 Jan 2010 07:00

RNS Number : 0220G
Scientific Digital Imaging Plc
25 January 2010
Β 

ο»Ώ

25 January 2010Β 

Scientific Digital Imaging plc

("SDI" or the "Group")

(AIM: SDI)

UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS TOΒ 31 OCTOBER 2009

The Board of Scientific Digital Imaging plc, theΒ AIMΒ quoted group focused on the needs of the scientific community, is pleased to announce its unaudited interim results for the six months endedΒ 31 October 2009.

Highlights

Sales increased by 7.0% to Β£3.42m (2008: Β£3.19m)

Gross margins improved to 57.8% (2008: 54.3%)

Synergies from earlier acquisitions became more evident

Operating profit Β£75k (2008: Β£270k, which benefited from a currency exchange gain of Β£110k)

Basic earnings per share 0.69p (2008: 1.37p)

Net cash position Β£163kΒ 

Harry TeeΒ CBE, Chairman of SDI, commented:

"Overall, we believe that the Group has strengthened its market position over the past six months and that its new products and initiatives provide considerable potential for profitable growth.

"We continue to seek further complementary acquisition targets for the Group."

--END-

Enquiries

Scientific Digital Imaging plc Β 

01223 727144

Harry TeeΒ CBE, Chairman

Phil Atkin,Β CEO

www.scientificdigitalimaging.comΒ 

GrantΒ ThorntonΒ Corporate FinanceΒ (Nominated Adviser)

020 7383 5100

Philip Secrett

Colin Aaronson

Astaire Securities plc

020 7448 4400Β 

Katie Shelton Β 

Bishopsgate Communications

020 7562 3350

Will Tindall

Gemma O'Hara

sdi@bishopsgatecommunications.com

Β 

Chairman's statement

Unaudited for the six months endedΒ 31 October 2009

I am pleased to report that the Group showed a sales increase of 7.0% to Β£3.42m (2008: Β£3.19m) in the six months toΒ 31 October 2009, despite the gloomy economic environment.Β Operating profit reduced to Β£75k (2008: Β£270k); the reduction was a consequence of currency exchange movements between the periodsΒ of Β£142k and increased investment in the Group's future. Basic earnings per share were 0.69p and fully diluted 0.60p (2008: 1.37p in both cases). The Group's net cash position decreased by Β£176k to Β£163k over the period. This reduction included a final consideration payment of Β£23k for the completion of the acquisition of Atik (formerly known as Artemis and Perseu), whilst working capital absorbed Β£96k.

Trading

Synoptics Limited ("Synoptics"), the Group's primary subsidiary, saw a small increase in its contribution margin despite a slight decrease in sales, whereas Atik demonstrated good improvements in both margin and turnover and provided a solid contribution to Group results.

Gross margin percentages improved by 3.5% to 57.8% (2008: 54.3%) as a result of product mix changes and the inclusion of Atik - a key supplier of Synoptics - within the Group, together with more advantageous exchange rates.

Administrative expenses increased to Β£1.87m (2008: Β£1.53m). A significant proportion of this rise is attributable to the administrative expenses of Atik and the ongoing listing costs ofΒ AIM; these were incurred over the full reporting period whereas the comparable 2008 figure only includes these expenses over the last part of that period. The Group also accelerated investment at Atik, increasing the number of employees from 3 to 7 since acquisition, in order to strengthen its sales channels and development capability. Costs denominated in US dollars also rose by approximately Β£60k as the result of changes in the exchange rate.Β 

TheΒ SynopticsΒ businessΒ in the US continued to grow. In the Syngene division, sales of higher-value systems have increased; this is a result of an investment in key developments in this area that deliver both greater performance and improved ease of use. The availability of stimulus funds has also provided some boost to sales in theΒ US.

Atik has recently invested in a campaign to grow sales in the importantΒ USΒ market, using the facilities of Synoptics Inc. inΒ MarylandΒ to streamline operations. It has begun work on its own image processing package, "Dawn", that will further establish Atik as a key company in the amateur astronomy market. "Dawn" uses the facilities of the image processing software toolkit developed over many years by Synoptics (a key part of its intellectual property) to provide facilities for the post-processing of astronomical images, presented via an attractive and innovative user interface.

The Synbiosis (microbiology) division of Synoptics launched a major new product, ProtoCOL 2, following a considerable investment in optical, mechanical and especially software technology. ProtoCOL 2 is a complete redesign of the previous successful colony counting instrument. Not only does the instrument provide high performance levels, but every effort has been dedicated to making it easy to use for both the end customer and the distributors that sell it. Market feedback has so far been very encouraging and sales are satisfactory.

Outlook

The benefits we anticipated from the consolidation of key suppliers into the Group have begun to be realised. Not only has this improved margins, but technical synergies have been achieved. The development of ProtoCOL 2 is expected to strengthen our standing in the microbiology market place. We anticipate that this innovative newΒ product, along with improvements to the high-value products in the Syngene range and both new products and new sales channels at Atik, will result in further growth.

We are pleased that our sales have proved robust through turbulent economic periods. Our experiences suggest that the funding of long-term research and development in our key markets has so far remained insulated from the general fluctuations of the economy.Β 

Overall, the Board believes the Group has strengthened its market position over recent periods and its new products and initiatives will contribute to a stronger second half. The Board now anticipates that market expectations for the full year will be exceeded. The Group continues to work on implementing its strategy to grow through acquisition and is actively seeking complementary businesses.Β 

consolidated Income statement

Unaudited for the six months endedΒ 31 October 2009

Unaudited

6 months toΒ 31 October 2009

6 months toΒ 31 October 2008

12 months toΒ 30 April 2009

Β£

Β£

Β£

Continuing operations

Revenue

3,417,800

3,192,820

6,753,869

Costs of sales

(1,440,890)

(1,458,007)

(2,946,222)

Gross Profit

1,976,910

1,734,813

3,807,647

AIM listing expenses

-

(41,958)

(344,956)

Currency exchange gains and losses

(31,746)

110,533

183,077

Administrative expenses

(1,869,828)

(1,533,562)

(3,539,519)

Operating profit

75,336

269,826

106,249

Financial income

70

5,458

4,677

Financial expensesΒ 

(32,208)

(20,064)

(54,137)

Profit before taxation

43,198

255,220

56,789

Income tax expense

1

68,260

(30,655)

(49,077)

Profit for the period

111,458

224,565

7,712

Earnings per share

BasicΒ Β 

2

0.69p

1.37p

0.05p

DilutedΒ 

0.60p

1.37P

0.04p

consolidated statement of comprehensive income

Unaudited for the six months endedΒ 31 October 2009

Unaudited

6 months toΒ 31 October 2009

6 months toΒ 31 October 2008

12 months toΒ 30 April 2009

Β£

Β£

Β£

Profit for the period

111,458

224,565

7,712

Other comprehensive income

Exchange differences on translating foreign operations

(46,683)

(2,993)

17,993

Total comprehensive income for the period

64,775

221,572

25,705

consolidated balance sheetΒ 

Unaudited atΒ 31 October 2009

Unaudited

Note

31 OctoberΒ 2009Β 

31 OctoberΒ 2008

30 AprilΒ 2009

Assets

Non-current assets

Β£

Β£

Β£

Property, plant and equipment

348,464

285,789

334,379

Intangible assets

740,308

666,982

702,058

Deferred tax asset

117,102

22,959

22,959

1,205,874

975,730

1,059,396

Current assets

Inventories

534,811

528,317

508,710

Trade and other receivables

1,254,086

1,376,880

1,244,846

Cash and cash equivalents

602,396

872,569

756,686

2,391,293

2,777,766

2,510,242

Total assets

3,597,167

3,753,496

3,569,638

Liabilities

Current liabilitiesΒ 

Β 

Β 

Β 

Trade and other payables

1,081,121

1,184,493

1,171,110

Provisions forΒ warranty

12,500

12,500

12,500

Borrowings

3

26,855

30,945

30,148

Tax liabilities

18,716

1,546

11,188

1,139,192

1,229,484

1,224,946

Non-current liabilitiesΒ 

BorrowingsΒ 

3

412,729

393,571

387,169

Deferred tax liability

121,898

98,225

111,101

534,627

491,796

498,270

Total liabilities

1,673,819

1,721,280

1,723,216

Net assets

1,923,348

2,032,216

1,846,422

Equity

Share capital

180,158

166,638

166,638

Merger reserve

2,606,016

2,606,016

2,606,016

Share premium account

187,142

38,327

38,327

Foreign exchange reserve

(31,638)

(5,941)

15,045

Own shares held by Employee Benefit Trust

(85,383)

(85,383)

(85,383)

Other reserves

248,940

389,051

399,124

Retained earningsΒ 

(1,181,887)

(1,076,492)

(1,293,345)

Total Equity

1,923,348

2,032,216

1,846,422

consolidated statement of CASH FLOWs

Unaudited for the six months endedΒ 31 October 2009

Unaudited

6Β monthsΒ toΒ 31 OctoberΒ 2009

6Β monthsΒ toΒ 31 OctoberΒ 2008

12 months toΒ 30 AprilΒ 2009

Β£

Β£

Β£

Operating activities

Profit for the period

111,458

224,565

7,712

Depreciation and amortisationΒ 

125,858

90,692

195,522

Profit on sale of property, plant and equipment

(2,811)

-

(12,145)

FinanceΒ expense

32,138

14,606

49,460

Taxation expenseΒ recognisedΒ in the income statement

(68,260)

30,655

49,077

Increase in warranty provision

-

2,500

2,500

Foreign exchange loss

(18,856)

(8,595)

(4,918)

Employee share based paymentsΒ 

9,776

9,475

15,346

Operating cash flow before movement in working capital

189,303

363,898

302,554

(Increase)Β /Β Decrease in inventoriesΒ 

(34,996)

(40,480)

5,137

Changes in trade and other receivables

(33,652)

(3,264)

(68,205)

Changes in trade and other payables

(27,541)

(42,589)

157,506

Cash generated from operations

93,114

277,565

396,992

Interest paid

(28,247)

(18,698)

(48,704)

Income taxesΒ paid

(26,797)

-

(7,730)

Cash generated from operating activities

38,070

258,867

340,558

Cash flows from investing activities

Purchase of property plant and equipment

(98,949)

(83,296)

(237,915)

Investment in development

(88,455)

(81,746)

(148,466)

Proceeds from saleΒ of property, plant and equipment

33,427

45,676

109,351

Purchase of acquisitions, net of cash acquired

(23,313)

(50,692)

(74,025)

Interest received

70

5,458

4,600

Net cash used in investing activities

(177,220)

(164,600)

(346,455)

Cash flows from financing activities

Capital element of finance leases

(17,515)

(15,066)

(30,785)

Issues of shares and warrants

2,375

41,659

41,659

Issue of loan stock

-

379,000

379,000

Net cashΒ used inΒ financingΒ activities

(15,140)

405,593

389,874

Net changes in cash and cash equivalents

(154,290)

499,860

383,977

Cash and cash equivalents, beginning ofΒ period

756,686

372,709

372,709

Cash and cash equivalents, end of periodΒ 

602,396

872,569

756,686

consolidated statement of changes in equity

Unaudited as atΒ 31 October 2009

Β 

Β 
Β Share Capital
Merger Reserve
Share premium
Own shares held by EBT
Other Reserves
Foreign exchange
Retained Earnings
Total
Β 
Β£
Β£
Β£
Β£
Β£
Β£
Β£
Β£
Balance at 1 May 2009
166,638
2,606,016
38,327
(85,383)
399,124
15,045
(1,293,345)
1,846,422
Share issued as deferred payment
13,330
-
146,630
-
(159,960)
-
-
-
Share options exercised
190
-
2,185
-
-
-
-
2,375
Share based payments
-
-
-
-
9,776
-
-
9,776
Transactions with owners
13,520
-
148,815
-
(150,184)
-
-
12,151
Profit for the period
-
-
-
-
-
-
111,458
111,458
Foreign exchange on consolidation of subsidiary
Β 
-
Β 
-
Β 
-
Β 
-
Β 
-
Β 
(46,683)
-
Β 
Β 
(46,683)
Total comprehensive income for the period
Β 
-
Β 
-
Β 
-
Β 
-
Β 
-
Β 
(46,683)
Β 
111,458
Β 
64,775
Balance at 31 October 2009
Β 
180,158
Β 
2,606,016
Β 
187,142
Β 
(85,383)
Β 
248,940
Β 
(31,638)
Β 
(1,181,887)
Β 
1,923,348
Β 
Β 
Β 

Β 
Β 
Share Capital
Merger Reserve
Share premium
Own shares held by EBT
Other Reserves
Foreign exchange
Retained Earnings
Total
Β 
Β£
Β£
Β£
Β£
Β£
Β£
Β£
Β£
Balance at 1 May 2008
163,306
2,606,016
-
(250,147)
22,872
(2,948)
(1,136,293)
1,402,806
Deferred tax on options
-
-
-
-
(4,202)
-
-
(4,202)
Employee Benefit Trust adjustment
-
-
-
Β 
164,764
-
-
Β 
(164,764)
-
Deferred consideration on acquisitions
-
-
-
-
Β 
319,920
-
-
Β 
319,920
Share options exercised
3,332
-
38,327
-
-
-
-
41,659
Share based payments
-
-
-
-
9,475
-
-
9,475
Equity element of loan stock
Β 
-
Β 
-
Β 
-
Β 
-
Β 
40,986
Β 
-
Β 
-
Β 
40,986
Transactions with owners
3,332
Β 
38,327
164,764
366,179
-
(164,764)
407,838
Profit for the period
-
-
-
-
-
-
224,565
224,565
Foreign exchange on consolidation of subsidiary
Β 
-
Β 
-
Β 
-
Β 
-
Β 
-
Β 
(2,993)
Β 
-
Β 
(2,993)
Total comprehensive income for the period
Β 
-
Β 
-
Β 
-
Β 
-
Β 
-
Β 
(2,993)
Β 
224,565
Β 
221,572
Balance at 31 October 2008
166,638
2,606,016
38,327
(85,383)
389,051
(5,941)
(1,076,492)
2,032,216
Β 
Β 

Β 
Share Capital
Merger Reserve
Share premium
Own shares held by EBT
Other Reserves
Foreign exchange
Retained Earnings
Total
Β 
Β£
Β£
Β£
Β£
Β£
Β£
Β£
Β£
Balance at 1 May 2008
163,306
2,606,016
-
(250,147)
22,872
(2,948)
(1,136,293)
1,402,806
Deferred tax on options
-
-
-
-
(4,203)
-
-
(4,203)
Employee Benefit Trust adjustment
-
-
-
Β 
164,764
-
-
Β 
(164,764)
-
Deferred consideration on acquisitions
-
-
-
-
Β 
319,920
-
-
Β 
319,920
Equity element of loan stock
-
-
-
-
Β 
40,986
-
-
Β 
40,986
Share options exercised
3,332
-
38,327
-
-
-
-
41,659
Share based payments
-
-
-
-
19,549
-
-
19,549
Transactions with owners
3,332
-
38,327
164,764
376,252
-
(164,764)
417,911
Profit for the period
-
-
-
-
-
-
7,712
7,712
Foreign exchange on consolidation of subsidiary
Β 
-
Β 
-
Β 
-
Β 
-
Β 
-
Β 
17,993
Β 
-
Β 
17,993
Total comprehensive income
-
-
-
-
-
17,993
7,712
25,705
Balance at 30 April 2009
166,638
2,606,016
38,327
(85,383)
399,124
15,045
(1,293,345)
1,846,422

Β 

notes to the interim financial statementsΒ 

Unaudited as atΒ 31 October 2009

The accompanying accounting policies and notes form an integral part of these interim financial statements.

reporting entity

Scientific Digital Imaging plc, a public limited company, is the Group's ultimate parent. It is registered inΒ EnglandΒ andΒ Wales. The consolidated interim financial statements of the Company for the period endedΒ 31 October 2009Β comprise the Company and its subsidiaries (together referred to as the "Group").Β 

Basis of Preparation

The unaudited consolidated interim financial statements are for the six months endedΒ 31 October 2009. These interim financial statements have been prepared in accordance with the accounting policies expected to be followed for the year endingΒ 30 April 2010, which are based on the recognition and measurement principles of IFRS as adopted by the European Union. The financial information for the year endedΒ 30 April 2009Β is based upon the audited statutory accounts for that year.

The financial statements have been prepared on the historical cost basis.

The consolidated interim financial statements are presented in British pounds (Β£), which is also the functional currency of the ultimate parent company.

The consolidated interim financial information was approved by The Board of Directors onΒ 22ndΒ January 2010.

The financial information set out in this interim report does not constitute statutory accounts as defined in sectionΒ 434Β of the Companies ActΒ 2006. The figures for the year endedΒ 30 April 2009Β have been extracted from the IFRS Statutory Financial Statements of Scientific Digital Imaging Plc which have been filed with the Registrar of Companies. The auditor's report on those financial statements is unqualified. The financial information for the six months toΒ 31 October 2009Β and for the six months toΒ 31 October 2008Β is unaudited.

principal accounting policies

The principal accounting policies adopted are consistent with those of the annual financial statements for the year ended 30 April 2009,Β except for the adoption of IAS 1 Presentation of Financial Statements (revised 2007) and IFRS 8 Operating Segments, and are those expected to be applied for the year ended 30 April 2010.

The adoption of IAS 1 (revised 2007) does not affect the financial position orΒ the profits of the Group, but gives rise to additional disclosures. The measurement and recognition of the Group's assets, liabilities, income and expenses is unchanged. IAS 1 (revised 2007) affects the presentation of owner changes in equity.Β 

The adoption of IFRS 8 has not changed the segments which are disclosed. Under IFRS 8 the accounting policy for identifying segments is based on the internal management reporting information that is regularly reviewed by the chief operating decision maker.

Β  The accounting policies have been applied consistently throughout the Group for the purposes of preparation of these interim financial statements.

1 TaxATION

Β 

Β 
6 mths to October
2009
6 mths to October
2008
year to
30 April 2009
Β 
Β£
Β£
Β£
Current tax expenses
15,086
680
6,660
Deferred tax (income) / expenses
(83,346)
29,975
42,417
Β 
Β 
Β 
Β 
Income tax (credit) / charge
(68,260)
30,655
49,077

The income tax expense recognised in the period is less thanΒ the effective rate ofΒ tax forΒ the group of 28% due to the availability of an additional deduction in the period for research and development and theΒ impact of initial recognitionΒ of tax losses brought forward across the group.

2 Earnings per share

The calculation of the basic earnings per share is based on the profits attributable to the shareholders of Scientific Digital ImagingΒ Plc divided by the weighted average number of shares in issue during the year, excluding shares held by the Synoptics Employee Benefit Trust. All earnings per share calculations relate to continuing operations of the Group.

Profits attributable to shareholders

Weighted average number of shares

BasicΒ earnings per share amount in pence

Period endedΒ 31 October 2009

111,458

16,073,650

0.69

Period endedΒ 31 October 2008

224,565

16,441,655

1.37

Year endedΒ 30 April 2009

7,712

15,841,221

0.05

The calculation of diluted earnings per share is based on the profits attributable to the shareholders of Scientific Digital Imaging plc divided by the weighted average number of shares in issue during the year, as adjusted for dilutive share options, dilutive deferred consideration and shares held by the Synoptics Employee Benefit Trust.

Diluted earnings per share amount in pence

PeriodΒ endedΒ 31 October 2009

0.60

Period endedΒ 31 October 2008

1.37

Year endedΒ 30 April 2009

0.04

The reconciliation of average number of ordinary shares used for basic and diluted earnings is as below:

31 October 2009

30 AprilΒ 2009

Weighted average number of ordinary shares used for basic earnings per share

16,073,650

15,841,221

Weighted average number of shares held by Synoptics Employee Benefit Trust

711,528

711,528

Weighted average number of ordinary shares used as deferred consideration

1,333,000

1,333,333

Weighted average number of ordinary shares under option

451,567

625,593

Weighted average number of ordinary shares used for diluted earnings per share

18,569,745

18,511,675

As at theΒ 31Β October 2009Β & 2008Β the company hadΒ outstandingΒ exercisableΒ share options and warrants. UnderΒ IAS 33Β the dilutive earnings per shareΒ is calculatedΒ assumingΒ that allΒ such instrumentsΒ are exercised in full. In October 2008 the exerciseΒ price for the options and warrantsΒ wasΒ the same or above the average market share price for the companyΒ soΒ the share options and warrantsΒ wereΒ considered to be non dilutive.Β 

TheΒ conversion of allΒ loan stockΒ would result in an increase in average weighted shares ofΒ 379,000. There would beΒ a corresponding increase in adjusted earnings due to the interest accruing thereon.Β The net effect is an enhancement of earningsΒ per share.

3 Borrowings

Β 
31 October
2009
31 October 2008
30 April 2008
Β 
Β£
Β£
Β£
Within one year
Β 
Β 
Β 
Finance leases
26,855
30,945
30,148
Β 
Β 
Β 
Β 
After one year and within two years
Β 
Β 
Β 
Loan stock
347,577
339,380
343,478
Other borrowings
65,152
54,191
43,691
Β 
412,729
393,571
387,169
Β 
Β 
Β 
Β 
Total borrowings
439,584
424,516
417,317

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IR DMGZMVZRGGZM
Date   Source Headline
13th Feb 20192:23 pmRNSDirector Dealings
13th Feb 20197:00 amRNSResults of PrimaryBid Offer
12th Feb 20194:31 pmRNSPrimaryBid Offer
12th Feb 20194:30 pmRNSPlacing and Acquisition
4th Feb 20197:00 amRNSAcquisition of Thermal Exchange Limited
29th Jan 20199:21 amRNSHolding(s) in Company
21st Jan 20195:39 pmRNSHolding(s) in Company
17th Jan 20197:00 amRNSAcquisition
4th Jan 20194:10 pmRNSHolding(s) in Company
21st Dec 20187:00 amRNSLong Term Incentive Plan Awards
18th Dec 20187:00 amRNSInterim Results
17th Dec 20182:12 pmRNSHolding(s) in Company
1st Nov 20182:51 pmRNSExercise of Options
29th Oct 201811:34 amRNSIssue of Options - Replacement
25th Oct 20183:00 pmRNSIssue of Options
9th Oct 20183:42 pmRNSDirector/PDMR Shareholding
26th Sep 20181:40 pmRNSDirector Dealings
25th Sep 201811:53 amRNSResult of AGM
25th Sep 20187:01 amRNSAGM Trading Update
25th Sep 20187:00 amRNSAcquisition of Fistreem International Limited
4th Sep 20187:00 amRNSPosting of Annual Report and Notice of AGM
17th Aug 20182:23 pmRNSHolding(s) in Company
27th Jul 20187:00 amRNSFinal Results
25th Jun 201812:10 pmRNSHolding(s) in Company
14th May 20184:09 pmRNSHolding(s) in Company
4th May 20187:00 amRNSDirectorate Appointment
1st May 20187:00 amRNSHolding(s) in Company
27th Apr 20187:00 amRNSTrading Update
24th Apr 20183:47 pmRNSHolding(s) in Company
24th Apr 20188:00 amRNSHolding(s) in Company
6th Feb 201810:46 amRNSIssue of Options
5th Feb 201811:52 amRNSDirector/PDMR Shareholding
2nd Feb 20187:00 amRNSQSI Acquisition
26th Jan 20187:00 amRNSInterim Results
10th Jan 201812:16 pmRNSHolding(s) in Company
4th Jan 20189:57 amRNSStatement re. potential small acquisition
11th Oct 20174:49 pmRNSHolding(s) in Company
26th Sep 20175:37 pmRNSResult of AGM
26th Sep 20177:00 amRNSAGM Statement & Directorate Change
21st Sep 20171:52 pmRNSHolding(s) in Company
6th Sep 201710:11 amRNSIssue of Equity and Total Voting Rights
1st Sep 20173:05 pmRNSIssue of Options
24th Aug 201711:55 amRNSDirector/PDMR Shareholding
24th Aug 20177:00 amRNSAcquisition of Applied Thermal Control Limited
26th Jul 20177:00 amRNSFinal Results & Directorate Appointment
26th May 20177:00 amRNSTrading Update
22nd May 20179:06 amRNSHolding(s) in Company
26th Apr 20172:19 pmRNSHolding(s) in Company
23rd Mar 20175:25 pmRNSHolding(s) in Company
15th Mar 201712:47 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.